SY57 - Hot Topics in Obesity Care in the GLP-1 Era: Biology, Safety, and Value in Chronic Disease

Symposium Chair(s)

• PK

  Preeti Kishore, MD

  Professor
  Jacobi Medical Center
  Scarsdale, NY, United States

  Disclosure(s): No financial relationships to disclose
• 

  Maria Escobar Vasco, MD

  Associate Professor. Program Director, Endocrinology
  UT Health San Antonio
  San Antonio, TX, United States

  Disclosure information not submitted.

GLP-1 receptor agonists have reshaped the treatment of obesity and diabetes, but their effects extend far beyond weight reduction and glycemic control. This session will examine emerging evidence on immunologic and oncologic actions of GLP-1s, critically evaluate potential safety concerns-including effects on the eye, thyroid, and muscle-and explore their cost-effectiveness in managing chronic diseases. Together, these talks provide a balanced view of the expanding biological, clinical, and economic dimensions of GLP-1-based therapies in contemporary metabolic medicine.

Presentations:

• 4:30 PM - 5:00 PM CT

  Cost-effectiveness of GLP-1 Agonist Therapy in Care of Chronic Diseases
  

  Symposium Speaker: David D. Kim, PhD – UNIVERSITY OF CHICAGO
• 5:00 PM - 5:30 PM CT

  GLP-1 Agonists Under the Microscope: Evaluating Risks
  

  Symposium Speaker: Carolina Solis-Herrera (she/her/hers) – University of Texas Health San Antonio
• 5:30 PM - 6:00 PM CT

  Beyond Appetite and Weight Loss: Unraveling Additional Biological Pathways of GLP-1 Therapies
  

  Symposium Speaker: Adrian Vella, MD, FRCP(Edin) – Mayo Clinic